Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2025-05-30 Regulatory Filings
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for domestic product approval for a new drug (코대원플러스정) to the Ministry of Food and Drug Safety. It details the clinical trial status, application dates, and includes a disclosure deferral notice. Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a formal regulatory disclosure of a material event, it falls under the 'Regulatory Filings' category.
2025-05-30 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure, which details changes to the terms of financial instruments (specifically conversion prices), falls under capital structure and financing updates. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most appropriate category for adjustments to conversion prices of debt securities.
2025-05-23 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Daewon Pharmaceutical Co., Ltd. for the first quarter of 2025 (ending March 31, 2025). It contains detailed financial data, business operations, management discussion, and financial statements, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
투자판단관련주요경영사항 (DW4421 제3상 임상시험계획 승인신청(미란성))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of a Phase 3 clinical trial application for the drug DW4421. This is a standard corporate disclosure of a material event. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-04-30 Korean
투자판단관련주요경영사항 (DW4421 제3상 임상시험계획 승인신청(비미란성) )
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of a Phase 3 clinical trial application for the drug DW4421. This is a standard corporate disclosure of a material event (clinical trial progress) to the regulatory body. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-04-30 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details specific changes to the company's board of directors, including the appointment of a new outside director and the resignation of an existing one. This falls directly under the category of Board/Management Information (MANG).
2025-03-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.